Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Operating Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Operating Expenses for 4 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 754.87% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.9 million, a 21.51% decrease, with the full-year FY2024 number at $6.6 million, down 69.16% from a year prior.
  • Other Operating Expenses was $6.8 million for Q3 2025 at Century Therapeutics, up from $1000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $13.1 million in Q4 2023 to a low of -$3000.0 in Q2 2024.
  • A 4-year average of $4.3 million and a median of $4.0 million in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 103.03% in 2024, then surged 754.87% in 2025.
  • Century Therapeutics' Other Operating Expenses stood at $10.0 million in 2022, then soared by 31.45% to $13.1 million in 2023, then tumbled by 68.25% to $4.2 million in 2024, then soared by 62.04% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Other Operating Expenses are $6.8 million (Q3 2025), $1000.0 (Q2 2025), and $4.2 million (Q4 2024).